Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX005N in adults with moderate to severe atopic dermatitis
ChiCTR2200063605Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX005N in atopic dermatitis (AD) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Percent change in Eczema Area and Severity Index score from baseline to week 16. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200063605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063605.